FDA To Seek Implementation Of FOIA Exemptions Through Proposed Rule
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency withdraws a direct final rule that would have implemented Freedom of Information Act exemptions relating to classified information, internal personnel rules and practices, and nondisclosure provisions after receiving two adverse comments.
You may also be interested in...
FDA To Include Additional FOIA Exemptions In Public Information Regs
The agency will incorporate existing Freedom of Information Act exemptions related to classified information, internal personnel records and nondisclosure provisions. The direct final rule will become effective unless the agency receives adverse comments.
Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.
RiskMAP Guidance Includes Plans For A Website
FDA is planning to develop a Risk Minimization Action Plan website, an agency risk management guidance states